Arrowhead Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how much money the company made or lost during the three-month period, helping you understand if the business is growing.
Contains detailed balance sheet and cash flow information investors need to evaluate company health quarterly.
New leadership with 25 years of healthcare investing experience can influence company strategy and decisions.
Contains detailed balance sheet and cash flow information investors need to evaluate company health quarterly.
Shows how much money the company made or lost during the three-month period, helping you understand if the business is growing.
Shareholders voted against executive compensation but approved new stock bonus plans and KPMG as auditor on March 19.
Contains detailed balance sheet and cash flow information investors need to evaluate company health quarterly.
Stocky reads Arrowhead Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Arrowhead Pharmaceuticals, Inc.'s most recent tracked filing was a 8-K on 4 Aug 2026: Reports fiscal 2026 results for quarter ended June 30.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.